Yahoo Finance Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q3 2023 Earnings Call Transcript
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q3 2023 Earnings Call Transcript November 7, 2023
Operator: Good morning and welcome to the Aquestive Therapeutics Third Quarter 2023 Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] As a reminder, this call will be recorded. I would now like to introduce your host for today's conference call, Bennett Watson of ICR Westwicke, Investor Relations. You may begin.
Bennett Watson: Thank you, operator. Good morning and welcome to today's call. On today's call, I am joined by Dan Barber, Chief Executive Officer and Ernie Toth, Chief Financial Officer, who are going to provide an overview of recent business developments and performance for the third quarter 2023, followed by a Q&A session. During the Q&A session, the team will be joined by Dr. Carl Kraus, Chief Medical Officer; Ken Marshall, Chief Commercial Officer and Dr. Steve Wargacki, Senior Vice President Research and Development. As a reminder, the company's remarks today correspond with the earnings release that was issued after market close yesterday. In addition, a recording of today's call will be made available on Aquestive's website within the Investors section shortly following the conclusion of this call.
To remind you, the Aquestive team will be discussing some non-GAAP financial measures this morning as part of its review of third quarter 2023 results. A description of these measures, along with a reconciliation to GAAP, can be found in the earnings release issued yesterday, which is posted on the Investors section of Aquestive's website. During the call, the company will be making forward-looking statements. We remind you of the company's Safe Harbor language as outlined in yesterday's earnings release, as well as the risks and uncertainties affecting the company as described in the Risk Factors section and in other sections included in the Company’s annual report on Form 10-K filed with the Securities and Exchange Commission on March 31st, 2023 and in our subsequent quarterly reports on Form 10-Q and current reports on Form 8-K filed with the SEC.
As with any pharmaceutical company, with product candidates under development and products being commercialized, there are significant risks and uncertainties with respect to the company's business and the development, regulatory approval and commercialization of its products and other matters related to operations. Given these uncertainties you should not place undue reliance on these forward-looking statements which speak only as of the date made. Actual results may differ materially from these statements. All forward-looking statements attributable to Aquestive or any person acting on its behalf are expressly qualified in their entirety by this cautionary statement and the cautionary statements contained in the earnings release issued yesterday.
The company assumes no obligation to update its forward-looking statements after the date of this conference call, whether as a result of new information, future events or otherwise, except as required under applicable law. With that, I will now turn the line over to Dan.
Dan Barber: Thank you, Bennett. I'm pleased to say that we have been able to accelerate the transformation of Aquestive over the last few months. We achieved important milestones across the clinical, regulatory and financial parts of the business since our last earnings call. Let me start with our most recent news. We were excited to refinance our debt last week and pleased with how our new lender, a large leading institutional investor has worked with us to maintain flexibility in our business. The $45 million facility provides for interest-only payments into mid 2026, well past our upcoming important clinical and regulatory milestones. Importantly, this agreement contains no revenue, EBITDA or cash covenants includes zero warrants and allows us the flexibility to launch or partner both Anaphylm and Libervant, as we deem appropriate if approved by the FDA.
And despite the Fed funds rate having increased by over 120% since our last financing in 2019, our interest rate remains fixed and increased by only one percentage point from the prior debt deal. We are truly pleased with this outcome. This brings me to another important financial point. This past quarter, marked the second quarter in a row, during which our non-GAAP adjusted EBITDA remained positive after removing our adjusted R&D costs. Simply put, if we weren't investing in the clinical development of Anaphylm Epinephrine Sublingual Film, our business would have a positive non-GAAP adjusted EBITDA through the first nine months of 2023. This, along with our continued strong revenue guidance, positions us well, as we start to focus on 2024.
In fact, our revenue guidance for 2023 has increased by over 25% from our original guidance provided earlier in the year. Ernie will talk more about our results in a few minutes. Now, let me turn to our pipeline. Investing in the clinical development of Anaphylm, remains the top priority. We continue to believe Anaphylm has the potential to transform the company and believe this transformation could happen in 2024. As we reported in October, we were pleased with the FDA's feedback on the design for our pivotal Phase three program. We are reaffirming our guidance that we will start the Phase three pivotal study this quarter and expect to provide top-line data in the first quarter of 2024. Completing our Phase three pivotal study will represent a major clinical milestone for the company.
We also continue to believe that patient demand for an oral epinephrine product for the treatment of severe allergic reactions including anaphylaxis, remain high. Now with nasal sprays delayed, we believe the benefits of an orally administered epinephrine rescue medication are more apparent than ever. Literature and survey data clearly show that many patients fail to carry their epinephrine rescue medical device. And even when they have it with them, patients fail to use their device. Our survey data suggests that patients often take an oral antihistamine pill such as Benadryl, before using their rescue medical device. We believe Anaphylm has the only oral rescue product under development for anaphylaxis has the potential to replace the incorrect use of antihistamines and thereby speed up time to symptom abatement.
One thing allergists universally agree on is that, early use of epinephrine is critical to treating anaphylaxis. Beyond the potentially significant carry-and-use benefits of Anaphylm, the pharmacodynamic clinical data from our recent studies provides the blueprint for a compelling improvement. According to medical experts, during anaphylaxis, the release of histamines causes blood vessels to expand, thereby rapidly dropping an individual's mean arterial pressure or MAP. Maintaining MAP supports the necessary pressure for vital organs, such as the brain and heart to function normally and reduces the risk of anaphylaxis-related outcomes such as loss of consciousness. In our studies, Anaphylm has been shown to preserve MAP in contrast to auto injectors that have not done so.
We are excited about the potential implications for patients. And our medical team will spend more time talking about this data, as we move into 2024. To sum up, we believe the projected timeline to FDA approval and market entry compared to the variety of nasal sprays under development is now much tighter than it was. The potential carry-and-use benefits remain significant. And our mean arterial pressure or MAP data continues to be compelling when compared to auto injectors. Now, turning to Libervant. We continue to progress towards our April 2024, FDA target action date for our NDA for patients between two and five years old. At this time, there are no open inquiries with the FDA regarding our NDA for this patient group. And we have no reason to believe the FDA won't meet the action date.
Market data shows a 31% increase in prescriptions in the two-to-five-year-old space during the third quarter 2023 when compared to third quarter of 2022. Well, over 90% up of these scripts were for diazepam rectal gel, the only FDA-approved drug for this age group. We continue to believe the need for an oral product in this space is significant and look forward to working with the FDA bring Libervant to these patients as soon as possible. We must remind you that in addition to the usual approval risks, we cannot guarantee that even with approval, the FDA will allow Libervant access to the US market. We also continue to believe that based on past behaviors, competitors may actively seek to block the use of Libervant despite its potential benefits to this critical patient population.
Now, let's turn to our epinephrine prodrug platform. I'm pleased today to talk about advancements in our epinephrine prodrug platform, which we have branded as the ADRENAVERSE. We have completed the initial formulation of a topical product using the ADRENAVERSE platform and plan on testing this formulation in humans in the coming months. Based on pre-clinical data we have seen rapid absorption of epinephrine across porcine tissue. As you know epinephrine is a vasoconstrictor and does not penetrate well through the skin. However, our ADRENAVERSE platform may allow for absorption thereby creating the potential use of this product for a variety of dermatological conditions. The unmet need and prevalence in some of these conditions is significant.
We look forward to sharing our findings as we progress this initiative. Our business development activities remain ongoing. Our Libervant and Anaphylm discussions continue in regions around the world. We also continue to believe that as we meet our expected clinical and regulatory milestones we will be able to generate significant funding from business development transactions our base business remains strong. We anticipate continued growth and remain focused on expanding our business capabilities in 2024. In summary, the third quarter was yet another crucial quarter for the company. We refinanced our debt we raised our revenue guidance and narrowed non-GAAP adjusted EBITDA guidance for 2023. We progressed our Anaphylm program and continue to plan for a Q4 start to our pivotal study.
We progressed our Libervant two-to-five-year-old application and remain on track. We completed our initial topical formulations of our ADRENAVERSE platform, and we continue to see growth in our base business. With that, I will turn the call over to Ernie.
Ernie Toth: Thank you, Dan and good morning everyone. By now, you have seen our financial results in our earnings release that was issued last evening. As we typically do, we will address most of the discussion related to the third-quarter 2023 results in the Q&A. During the third quarter, we continued to execute on our financial strategy to strengthen our financial position by refinancing our outstanding debt as well as managing expenses to extend our cash runway to support the continued development of our lead product, Anaphylm, the first and only non-device based orally delivered epinephrine product. We recently announced the refinancing of our outstanding obligations under the 12.5% senior secured notes having a maturity date of June 30th, 2025.
The new financing of $45 million by a large leading institutional investor will be used to repay all outstanding obligations under the prior credit facility and for general corporate purposes. The notes are senior secured obligations of Aquestive and will mature on November 1st, 2028. The notes bear interest at a fixed rate of 13.5% per year payable quarterly. Principal will be repaid starting on June 30th, 2026. Importantly, the notes contain no revenue or cash covenants and no warrants for purchase of the company's common stock were issued under the terms of the transaction. The structure of this non-dilutive refinancing transaction maximizes our flexibility in the short-term and reduces our cash requirements by approximately $28 million through June 30, 2025, the due date of the original credit facility.
Despite very difficult market conditions, the investors' willingness to invest in our future represents an important step forward in the continued growth of Aquestive. Now let's turn to the recap of our quarterly and year-to-date financial results. Excluding the impact of prior year proprietary sales of Sympazan, total revenues increased from $9.2 million in the third quarter of 2022 to $13 million in the third quarter of 2023. This 42% increase in revenue was primarily driven by higher revenue from the company's five out-licensed products. Total reported revenues were $13 million in the third quarter 2023 compared to $11.5 million in the third quarter 2022. For the third quarter 2023, compared to the prior period, we saw a 193% increase in license and royalty revenue, primarily due to Sympazan and Azstarys, a 36% increase in manufacture and supply revenue from Suboxone and Sympazan and a 24% increase in co-development and research feeds.
Excluding the impact of prior year proprietary sales of Sympazan, total revenues increased from $29.9 million for the nine months ended September 30, 2022 to $37.4 million for the nine months ended September 30, 2023, an increase of 25%. Total reported revenues were $37.4 million for the nine months ended September 30, 2023 compared to $37 million for the nine months ended September 30, 2022. The increase was primarily due to increases in manufacture and supply revenue and license and royalty revenue offset by the absence of proprietary product sales subsequent to the out-licensing agreement with Assertio in October 2022. Net loss for the third quarter 2023 was $2 million or $0.03 loss per share. The net loss for the third quarter 2022 was $12.5 million or $0.23 loss per share.
The change in net loss was primarily driven by increases in revenues, as previously described, decreases in selling general and administrative expense, including severance costs and lower administrative costs in our commercial organization subsequent to the out-licensing of Sympazan in October 2022, a decrease in non-cash interest expense and a decrease in research and development costs and expenses. Our net income for the nine months ended September 30, 2023 was $0.2 million. The net loss for the nine months ended September 30, 2022 was $42.1 million or $0.90 loss per share. Non-GAAP adjusted EBITDA loss was $1.3 million in the third quarter 2023 compared to a non-GAAP adjusted EBITDA loss of $7.7 million in the third quarter of 2022. Non-GAAP adjusted EBITDA income, excluding our continued investment in research and development, was $1.7 million for the third quarter of 2023 compared to a non-GAAP adjusted EBITDA loss, excluding adjusted R&D expenses of $4.6 million in the third quarter of 2022.
Cash and cash equivalents were $24.9 million, as of September 30, 2023. Under the at-the-market or ATM facility, we access $0.2 million during the third quarter of 2023 and $5.3 million during the nine months ended September 30, 2023. The ATM facility has approximately $27.8 million available at September 30, 2023. In addition, during the nine months ended September 30, 2023, approximately 8.7 million common stock warrants were exercised with proceeds of approximately $8.3 million. We continue to be focused in 2023 on the advancement of our epinephrine program and commencing our pivotal PK clinical trial in the fourth quarter. Suboxone currently continues to retain a strong presence in both the US commercial and CMS markets and continues to provide a growth opportunity outside the US.
We anticipate additional revenue from our licensed products during the remainder of 2023. And moreover, we will continue to focus on capital conservation to extend our cash runway as far as possible. As outlined in the press release issued last night after market close, based on our third-quarter results and positive outlook for the remainder of 2023, we have revised our full-year 2023 financial guidance as follows. Total revenues increased to approximately $47 million to $50 million from $44 million to $48 million. And non-GAAP adjusted EBITDA loss narrowed to approximately $14 million to $17 million from $19 million to $22 million. Please note our revenue guidance for 2023 no longer includes proprietary net sales for Sympazan, due to the out-licensing agreement with Assertio but does include manufacture and supply revenue and royalty fees.
In addition, our guidance for 2023 includes continued focused R&D investments related to the continued development of Anaphylm, the first and only non-device based orally delivered epinephrine product. With that I will now turn the line back to the operator to open the line for questions.
See also 5 Best Home Connected Fitness Equipment and 20 Most Valuable Financial Companies in the World.
To continue reading the Q&A session, please click here.
